Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants
Conditions: Peanut Allergy; Multi-food Allergy Interventions: Drug: Omalizumab; Drug: Placebo for Omalizumab; Drug: Multi-Allergen Oral Immunotherapy; Drug: Placebo for Multi-Allergen Oral Immunotherapy; Other: Double-Blind Placebo-Controlled Food Challenge Based Treatment Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); Genentech, Inc.; Novartis Pharmaceuticals Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials